裕興科技(08005.HK)擬4,800萬元認購Profound View Group共8.41%股權
裕興科技(08005.HK)公佈,於今年12月1日,直接全資附屬利富與目標公司Profound View Group就利富認購目標公司普通股股份訂立認購協議。認購事項的代價將爲4,800萬元。完成後,利富將持有目標公司經擴大後股本合共8.41%。目標集團的財務業績將不會併入集團綜合財務報表。
於公告日期,目標公司由Tibetan持有42.6%,而從玉則持有64.68%,從玉爲公司執行董事、行政總裁及主要股東,因此訂立認購協議構成公司關連交易。
目標公司持有深見醫藥100%已發行股本,而深見醫藥則持有深圳深見100%股權,進而持有武漢廣行100%股權。公司認爲,認購事項爲集團提供了擴大其對綜合醫療保健及生物製藥行業的投資,並提升股東價值的機會。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.